Sagimet Biosciences Inc.
SGMTNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|
| Revenue | — | — | $2.0M | — |
| Operating income | −$56.9M | −$54.5M | −$30.7M | −$31.1M |
| Net income | −$51.0M | −$45.6M | −$27.9M | −$30.5M |
| Total assets | $116.5M | $160.3M | $96.7M | $33.0M |
| Total liabilities | — | — | $5.7M | $5.4M |
| Equity | $111.4M | $155.8M | $91.1M | −$186.9M |
| EPS (diluted) | $-1.58 | $-1.45 | $-2.66 | $-165.20 |
| Shares out. | 32.3M | 31.4M | 0 | 185,084 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −45.8%
- Return on assets
- −43.8%
- Return on capital (ROCE)
- −51.1%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $3.44
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −4.6%clean
- Piotroski F-Score
- 1/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 1 good- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Kpcb Pandemic & Bio Defense Fund LlcPassive (13G)Dec 18, 2025
- Woodline Partners LpPassive (13G)Nov 14, 2025
- Point72 Asset Management, L.P.Passive (13G)Aug 14, 2025
- Ap11 LtdPassive (13G)Jun 24, 2025
- New Enterprise Associates 13 LpPassive (13G)May 13, 2025
- Blue Owl Capital Holdings LpPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Rozek ElizabethOfficer — Chief Legal & Admin. Officer | Feb 19, 2026 | Grant | 44,000 | $0.00 |
| Martins Eduardo BrunoOfficer — Chief Medical Officer | Feb 19, 2026 | Grant | 44,000 | $0.00 |
| Happel DavidOfficer — President & CEO | Feb 19, 2026 | Grant | 128,000 | $0.00 |
| Chauche ThierryOfficer — Chief Financial Officer | Feb 19, 2026 | Grant | 44,000 | $0.00 |
| Happel DavidOfficer — President & CEO | Feb 10, 2026 | Sell | 12,101 | $5.36 |
| Chauche ThierryOfficer — Chief Financial Officer | Feb 10, 2026 | Sell | 1,312 | $5.36 |
| Martins Eduardo BrunoOfficer — Chief Medical Officer | Feb 10, 2026 | Sell | 3,640 | $5.36 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4.2M | 4.3 | -7.1% |
| Apr 30, 2026 | 4.5M | 1.0 | +26.0% |
| Apr 15, 2026 | 3.6M | 10.4 | +11.6% |
| Mar 31, 2026 | 3.2M | 7.8 | -15.2% |
| Mar 13, 2026 | 3.8M | 12.6 | +3.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 12, 2026
- Entered a material agreementApr 28, 2026
- Regulation FD disclosureApr 27, 2026
- Results of operations · Regulation FD disclosure · Other material eventApr 27, 2026
- Director / officer change · Other material eventApr 21, 2026
- Results of operations · Regulation FD disclosureMar 11, 2026
- Regulation FD disclosureFeb 2, 2026
- Regulation FD disclosure · Other material eventDec 18, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4OWNERSHIP DOCUMENTJun 1, 2026
- 4OWNERSHIP DOCUMENTJun 1, 2026
- 4OWNERSHIP DOCUMENTJun 1, 2026
- 4OWNERSHIP DOCUMENTJun 1, 2026
- 4OWNERSHIP DOCUMENTMay 14, 2026
- 3OWNERSHIP DOCUMENTMay 14, 2026
- 8-KFORM 8-KMay 12, 2026
- 10-QMay 12, 2026
- 8-KFORM 8-KApr 28, 2026
- 424B5Apr 28, 2026
- 8-KFORM 8-KApr 27, 2026
- 8-KFORM 8-KApr 27, 2026
- ARSApr 21, 2026
- DEF 14AApr 21, 2026
- 8-KFORM 8-KApr 21, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.